13 November 2018, The global Circulating Tumor Cells Market is primarily fueled by high incidence of cancer and other lifestyle diseases, growing global population, and technological developments. CTCs are cancer cells that start drifting away from metastatic or primary tumor sites and start circulating in the bloodstream. These are primarily utilized in molecular analysis, such as liquid biopsies. Rising adoption of companion diagnostic options & personalized medicine for total eradication of onsite cancer could create lucrative opportunities for further market progress.
The global industry is at present characterized by translational research and genomics. These systems lead to better detection, analysis, and enumeration of circulating tumor cells present in patients. The need for oncology diagnosis, screening, and therapy propels the overall industry. However, complexities in the isolation of tumor cells can impede market growth during the forecast period (2016 to 2024).
Browse Details of Report @ https://www.hexaresearch.com/research-report/circulating-tumor-cells-industry
The worldwide industry is segmented on the basis of technologies, applications, and regions. Based on technologies, the categories are tumor cell detection & enrichment, centrifugation, molecular, immunomagnetic, optical, filtration, and immunological. Tumor cell enrichment & detection dominated the market in 2013. High degree of accuracy, faster outcomes, and easy sample collection are factors that fuel this segment. It may grow at a whopping CAGR of 27% from 2016 to 2024. Also, immunomagnetic & immunological technologies may gain popularity during this period. This owes to their compatibility with all genome sequencing and the capacity to facilitate effective analysis with smaller blood samples.
The areas of application are colorectal cancer, prostate cancer, and breast cancer. The industry was led by the breast cancer segment in 2013. Rising incidence of breast cancer attributes to high frequency of malignancy and the growth of circulatory tumor cells from small sized primary tumors. What makes cancer a terminal disease is the spreading of cancer cells to the healthier organs & body cells; a phenomenon known as metastasis.
Geographically, the industry is categorized into North America, Europe, Asia Pacific, and Rest of the World. North America is a strong regional market that is driven by favorable government initiatives, exhaustive R&D activities, and updated technology infrastructure. Growing patient awareness too plays a vital role in positively influencing this regional market. It is expected that Asia Pacific economies, such as China and India will witness considerable growth during the forecast period. The region is propelled by growing awareness about hospital acquired infections and surging healthcare expenditure.
Prominent companies operating in the worldwide Circulating Tumor Cells Market are AVIVA BioSciences Corporation; Advanced Cell Diagnostics Inc.; Silicon Biosystems, Vitatex Inc.; and Veridex LLC. Clinicians & researchers for a long time have tried developing effective methods for cancer screening & its progression. Commonly used methods involve blood tests for screening biomarkers. For example, PSA (prostate-specific antigen) levels are indicators of prostate cancer. Other frequently employed screening methods are MRI (magnetic resonance imaging) or computed tomography. However, one particular approach that holds good promise is the analysis of CTCs (circulating tumor cells). Scientists point out that the genetic analysis of CTCs could throw light on patients’ suitability for targeted cancer therapies. This could help determine the mutational landscape of tumors as well.
Browse Related Category Reports @Cancer Biologics Market – The global cancer biologics market size is expected to reach USD 87.60 billion by 2024 and is anticipated to grow on account of rising prevalence of cancer, increasing demand for biological and targeted drug therapies.
Bioreactors Market – The worldwide bioreactors market is projected over USD 550 million by 2024, growing at a CAGR above 18% during the forecast period (2016-2024). It is driven by the adoption of single-use bioreactors (SUBs) & hybrid bioreactors and demand for biologics.
About Us:Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
More Information Visit @ www.hexaresearch.com
Media ContactCompany Name: Hexa ResearchContact Person: Ryan ShawEmail: Send EmailPhone: +1-800-489-3075Address:Felton Office Plaza, 6265 Highway 9 City: FeltonState: California 95018Country: United StatesWebsite: www.hexaresearch.com/research-report/circulating-tumor-cells-industry
